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 Viridicatumtoxin A is a unique tetracycline-like aromatic polyketide first isolated 
as a mycotoxin from Penicillium viridicatum in 1973. Along with its 5-oxo derivative, 
viridicatumtoxin B, discovered in 2008 from the liquid fermentation cultures of another 
Penicillium sp. (strain FR11) has exhibited cytotoxicity against the NCI-H460 human 
lung carcinoma cell line, KB3-1 human cervix carcinoma cell line, and SW620 human 
colon carcinoma cell line with reported IC50 values of 1.0 µM, 2.5 µM and 1.0 µM 
respectively. Based on the scarcity and the more bioactive properties of viridicatumtoxin 
B, Nicolaou and coworkers in 2013 achieved the total synthesis of viridicatumtoxin B; 
albeit through a lengthy protocol which would not be scalable. In this context, and as part 
of our ongoing research centered on the optimization of drug leads for the treatment of 
cancer, my project is focused on the enhanced production of viridicatumtoxin A from 
fungal cultures which would provide materials for synthesis of more bioactive analogues.
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CHAPTER I 
INTRODUCTION 
 
 
1.1 Overview of Cancer 
 Cancer is a group of diseases in any part of the body that results from unregulated 
division and growth of randomly mutated cells possessing metastatic capabilities. Unlike 
normal cells, cancer cells are not subject to cell regulatory mechanisms like confinement 
to a specific space within a tissue as well as apoptosis. Cancer diagnosis is often 
associated with panic, apprehension, and despondence. 
 Historical records date the existence of different kinds of cancer as early as the 
discovery of bone tumors on autopsies of primitive Egyptian mummies.1 Also, the 
earliest documentation of cancer (not called cancer at the time) was found on the Edwin 
Smith Papyrus, where the treatment of eight characteristic cancer cases were described.2 
It was reported that ancient Chinese and Arabic medical writings described conditions 
that are closely related to cancer in signs and symptoms.1  
 In the 4th century, the “Father of Medicine”, Hippocrates coined carcinos (non-
ulcer forming) and carcinoma (ulcer-forming) derived from the Greek word Karkinos 
(meaning crab), to describe the finger-like growth pattern and the tenacity with which 
cancer intrudes on surrounding cells.2 Cancer, which is the Latin word for crab, was first 
used by Celsus, an early Roman Physician.2 
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 Classification of cancer is along the line of their cell of origin. Carcinomas 
constituting 80 % of all human cancer are of epithelial origin, while cancer of the 
connective or supportive tissues like bones, muscles, cartilage, tendons, and fibrous 
tissues are known as sarcomas.3 The buildup of immature and abnormal blood cells in the 
body due to cancer originating in hematopoietic stem cells is called leukemia. Cancers of 
the lymphatics and immune cells are called lymphomas and myeloma respectively. 
 Interest in cancer reportedly gained momentum in the late 18th century to the 
early 19th century after the scourge of infectious diseases was curtailed.1 This has 
resulted in breakthroughs in early detection and quality of treatment at patients’ disposal, 
but in spite of this, cancer is still a leading cause of death and continues to persist as a 
prime public health concern all across the globe.4 For example, the number of deaths due 
to cancer in first and developing countries was estimated to be about 7.4 million in 2004 
and about 8.2 million deaths were registered in 2012.5  These deaths are estimated to hit 
11.5 million by 2030.5-6 In the United States alone, where cancer is the second leading 
cause of death (except for American Indians or Alaska Natives and Asians or Pacific 
Islanders) after heart related diseases, it has been projected that over 1.7 million new 
cancer cases and over 600, 000 cancer deaths will be recorded in 2018.7 Thus, it is 
imperative to find new therapeutics to combat this deadly disease. 
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 1.2 History of Cancer Chemotherapy 
 Discovery of new leads in anticancer drug development is the central focus of our 
research laboratory.8 In the US alone, organizations like the National Cancer Institute 
(NCI) and a number of pharmaceutical companies have spent several billions of dollars in 
anticancer drug development studies.9  
 Herbal preparations were the first reported cancer treatment administered in 
history.10 Up until the 1960s, cancer treatments, which mostly combined surgical excision 
with radiotherapy, resulted in a low survival rate of 33% ascribable to metastases from 
undetected and minuscule cancer cells.11 This occurrence brought supportive 
chemotherapy into the fray, where drugs were coupled with surgery and/or radiation 
treatments.11 This mode of treatment has become the effective standard of care for cancer 
patients with various types and stages of cancer the world over.11 
 As with many scientific discoveries, the earliest effective anticancer therapeutics 
came by way of knowledge-based and/or chance discoveries for example, nitrogen 
mustard exposure in World War I soldiers caused suppression of lymphoid and myeloid 
cells, and removal of ovaries in women often minimized breast cancers.10  
 Sources of anticancer therapeutics would however, have to undergo a series of 
evaluations, which may take several years to decades before becoming a drug.10 These 
sources include nature, which has often times provided compounds as new leads in the 
discovery of novel anticancer agents as well as other drugs.12 
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 1.3 Importance of Nature to Drug Discovery 
 Nature has been responsible for the emergence of wide-ranging therapeutic drugs 
for years.13 For a fact, natural sources have demonstrated beyond doubt that they are the 
most abundant source of novel chemical entities for biological studies and a valuable 
source for drug discovery.14 Natural products have contributed immensely to the world of 
drug discovery, especially over the past 30 years, with 79% of new small molecule 
anticancer drugs and 68% of the antiinfectives.15 Natural products account for 5% of the 
1,031 new chemical entities approved as drugs by the US Food and Drug Administration 
(FDA) between 1981 and 2002, and natural-product-derived compounds made up another 
23%.16 Those contributions include inspiration for many therapeutic agents for regulation 
of immune response, cancer, infectious diseases (both bacterial and fungal), and lipid 
disorders. For example, between the 1940s to the end of 2014, 83% of approved anti-
cancer drugs were either natural products per se/based/mimicked natural products in one 
form or another.17  
 They have been successful because of their function-first approach as opposed to 
the target-first approach, which some pharmaceutical companies employ.16  These natural 
products are often used as starting points for drug discovery in combinatorial chemistry, 
where highly desired analogues can then be prepared.18  
 Natural product chemistry pertains to a group of low molecular weight 
compounds, known as secondary metabolites, with potent physiological activities.6 The 
depth of chemical diversity of natural products stem from the fact that they have evolved 
over a significant period of time.18 A number of important anticancer drugs like: taxol, 
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camptothecin, romidepsin and etoposide (Figure 1), which are naturally derived or 
inspired, demonstrate this chemical diversity.19 
1.4 Fungi are a Rich Source of Natural Products 
 The fungal kingdom is said to be the second largest among the eukaryotes, with a 
recently proposed estimate of 1.5 to 5.1 million species20 but with only about 135 000 are 
classified in literature and a fewer number analyzed chemically.21 Many fungal species 
are sources of bioactive secondary metabolites which may be produced to neutralize 
competitions from bacteria, algae, and other fungi in their intricate environment.22 These 
secondary metabolites serve as useful leads for drug discovery and have culminated in 
pharmaceutical successes (Figure 2) such as penicillin (antibiotic), griseofulvin 
(antifungal), compactin (cholesterol-lowering agent), fingolimod (receptor-modulating 
agent), ergometrine (uterine vasoconstrictor) and psilocybin (anxiolytic).  
 Terrestrial plants were the sole source of natural products-derived drugs until the 
discovery of penicillin in the early 20th century (1940), which shifted focus to other 
natural sources such as fungi.19 The availability of molecular tools such as DNA 
barcoding for fungal identification has aided the popularity of the use of fungi in natural 
products research.20  
 Fungal secondary metabolites are built from simple materials including: organic 
acids, sugars, amino acids, terpenes, and nitrogenous bases such as purines and 
pyrimidines. They are categorized into polyketides, non-ribosomal peptides, terpenes, 
and indole terpenes, among others.6  
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Figure 1. Nature-Derived Anticancer Drugs. 
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Figure 2. Pharmaceutical Successes from Fungi. 
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 Fungi are a proven source of natural products because it is well documented that 
they produce diverse secondary metabolites that display a wide range of biological 
activities.23 While true, it is believed that they are yet to be explored fully because studies 
into fungal metabolites have yet to culminate in the development of a blockbuster 
anticancer drug.24 
1.5 History of Viridicatumtoxins 
 The fungal metabolite, viridicatumtoxin A has potential cytotoxic and 
antibacterial activities. In 2005, investigation of secondary metabolites from Aspergillus 
unilateralis by Capon and co-workers revealed viridicatumtoxin A as having both these 
activities.25  
 Studies on the cause of swine hepatotoxicity from feed contaminated by the 
fungus, Penicillium viridicatum, led to further studies resulting in the isolation of 
viridicatumtoxin (as it was called then) in 1973 as a toxic compound.26 Cultures of 
several isolates of P. viridicatum grown on moist maize proved toxic to guinea pigs 
producing characteristic renal, hepatic and splenic lesions microscopically.26  
 Viridicatumtoxin A is a tetracycline-like (containing the naphthacenedione core) 
aromatic polyketide. While it was first isolated as a mycotoxin from Penicillium 
viridicatum,26 it has since been reported to be produced by several species of 
Penicillium.27 
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 Its color is bright yellow when newly isolated, and its molecular formula of 
C30H31NO10 was determined by elemental analysis and high-resolution mass 
spectroscopy.26 It differs from tetracycline in the presence of a spirobicyclic ring, forming 
an additional two rings, the absence of the 4-dimethylamino moiety, and its fungal origin 
as opposed to the largely bacterial origin of the tetracyclines.27 Its first structure 
elucidation was done by X-ray crystallographic methods in 1976.28                   
 In 2013, Nicolaou et al. revised crystal structure of viridicatumtoxin and renamed 
it viridicatumtoxin A (Figure 3).27 Perhaps the most significant analogue to date is a 5-
oxo derivative which was termed viridicatumtoxin B and was discovered in 2008.29 In 
early 2012, Yi Tang and co-scientists identified a new analogue, previridicatumtoxin 
while studying the gene clusters involved in the biosynthesis of viridicatumtoxin A in 
Penicillium aethiopicum.30 Later the same year, Tomoda et al. reported the isolation of 
viridicatumtoxin A alongside a new analogue, spirohexaline, from a liquid culture of 
Penicillium brasilianum.31 Capon and co-researchers isolated the latest analogues (Figure 
4), viridicatumtoxins D−F and previously isolated compunds like spirohexaline and 
previridicatumtoxin from scaled up cultivation of a Paecilomyces sp. (CMBMF010) in 
2015.27  
 The pursuit of promising cytotoxic drug leads from the perspective of natural 
products with emphasis on fungal secondary metabolites is the longest running project of 
the Oberlies group till date. Our interest in viridicatumtoxin A is a product of this search.8 
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1.6 Previous Isolations of Viridicatumtoxin A in Literature   
 The first isolation of viridicatumtoxin A was from cultures of a strain of P. 
viridicatum, CSIR 1029, grown on 3 kg of wet sterile maize meal.26 The extractions were 
done exhaustively with an undisclosed ratio of CHCl3 to MeOH resulting in extracts 
weighing 240 g upon drying.26 The extracts were partitioned with an undisclosed ratio of 
CHCl3 to H2O mixture.
26 The organic (CHCl3) layer, which was evaporated to dryness 
weighing 82 g, was subjected to further partitioning, this time, with an undisclosed ratio 
of hexane to MeOH (90%) mixture.26 The hexane layer was evaporated to yield 35 g of a 
nontoxic sample and the 90% MeOH layer was evaporated to yield 46 g of toxic 
sample.26 The 90% MeOH layer was purified to yield 11 g of griseofulvin and 4 g of 
viridicatumtoxin A via column chromatography on formamide-impregnated cellulose 
powder using hexane and benzene mixtures as the mobile phase.  
 In 2008, cultures of Penicillium sp., strain FR11, were grown on 80 mL of yeast 
extract peptone sucrose (YPS) liquid medium in a 500 mL Erlenmeyer flask.29 The 
culture flask was place on a rotary shaker (150 rpm) for 3 days at 28°C.29 From the 
culture, 15 mL were inoculated into a 1000 mL Erlenmeyer flask to enhance the growth 
of the fungus and therefore, the production of active compounds.29 These cultures were 
placed on a rotary shaker (150 rpm) at 28°C for 7 days and were extracted 
comprehensively with 50% acetone with the resulting extracts dried in vacuo.29 The 
extract, after being reduced to a combined aqueous solution, was extracted three times 
with the same volume of EtOAc.29 Initial fractionation of the EtOAc extract (5.0 g) was 
done using an YMC s-150 mm octadecyl-silica (ODS) column chromatography.29 
11 
 
 The gradual elution followed the method gradient of MeOH to H2O with the 
active fractions coming out with the 80 : 20 and 90 : 10 gradients. These active fractions 
were combined and dried in vacuo.29 This combined active portion was then dissolved in 
MeOH and  purified using YMC C-18 reverse phase high performance liquid 
chromatography (HPLC) system.29 Viridicatumtoxin A and B eluted at retention times of 
32.1 and 38.2 mins, respectively, with MeOH to H2O at 85 : 15 gradient.
29 
 The third isolation of virdicatumtoxin A reported in 2015 was cultured both on 
peptone yeast extract glucose (PYG) agar and rice solid media.27  
For the Agar study, PYG plates (n = 100) were inoculated with a lone colony of the 
fungal strain CMB-MF010 (Paecilomyces sp.) and were incubated at 26.5 °C for 25 days. 
These samples were harvested and diced (∼1cm3) after comprehensively extracting with 
EtOAc.27 The resulting extract weighed 1173 mg after drying in vacuo.27 Partitioning 
with a series of soluble solvents yielded: hexane fraction  (153.9 mg), CH2Cl2 fraction 
(700.0 mg), and MeOH fraction (144.0 mg).27 SPE (C-18) chromatography of the CH2Cl2 
fraction with a 70% H2O/MeOH to MeOH gradient elution yielded fractions 1 and 2 
weighing 38.7 mg and 96.3 mg respectively.27 Preparative HPLC of both fractions using 
a C-8 column and gradient elution from 35% - 52% CH3CN to H2O over 5 mins, 
followed by 52% - 57% CH3CN to H2O over 10 mins yielded in order of retention time, 
viridicatumtoxin F (2.6 mg), viridicatumtoxin E (7.5 mg) and viridicatumtoxin D (8.2 
mg) (for fraction 1) and viridicatumtoxin A (14.1 mg) and viridicatumtoxin B (0.6 mg) 
for fraction 2.27  
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Figure 3. Previous (left) and Revised (right) Structures of Viridicatumtoxin A. 
 
 
 
 For the rice solid media study, fermentation was performed by using an inoculum 
of CMB-MF010 from one of the PYG agar plates above and transferring into a sterile 
solid rice medium in a 1000 mL Erlenmeyer flask, which was then incubated at 26 °C for 
25 days.27 The resulting fungal culture was extracted with EtOAc completely and dried in 
vacuo, weighing 673.0 mg.27 Partitioning with a series of soluble solvents yielded: 
hexane fraction (375.9 mg), CH2Cl2 fraction (161.1 mg), and MeOH fraction (22.1 mg).
27 
Starting with 90% H2O/MeOH to MeOH, SPE (C-18) chromatography of the CH2Cl2 
fraction yielded 10 subfractions.27 Subfractions at 50%, 40% and 30% H2O/MeOH were 
combined and preparative HPLC of the combined fractions in a C-3 column using 
isocratic elution of 45% CH3CN to H2O over 20 min generated viridicatumtoxin A (7.4 
mg) and viridicatumtoxin C (2.9 mg), while a fraction at 10% H2O/MeOH generated 
spirohexaline (0.3 mg) and previridicatumtoxin (0.4 mg) with preparative HPLC gradient 
elution of 50% - 65% CH3CN to H2O.
27
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1.7 Organic Synthesis of Viridicatumtoxin Analogues 
 Nicolaou and co-workers, inspired by the potent antibiotic properties, the scarcity, 
structural complexity, and the incomplete structural assignment of viridicatumtoxin B, 
achieved its total synthesis (3.5 mg), albeit through a lengthy protocol involving 39 
steps.32 The design of the total synthesis was based on retrosynthetic analysis through 
which they were able to transform viridicatumtoxin B into four simpler building blocks 
each of which was accessed using the same method.33 The pursuit of the total synthesis 
began with the construction of the four main building blocks: an allylic bromide, a cyclic 
anhydride, a quinone monoketal, and an isoxazole phenyl ester.32 The four building 
blocks were then successfully connected together through convergent synthetic 
mechanisms to form viridicatumtoxin B.32  
 The successful total synthesis of viridicatumtoxin B enabled its structure to be 
revisited, its earlier assigned epoxy hemiacetal structure to be correctly reassigned as 
hydroxy ketone.33 Therefore, the absolute configuration of viridicatumtoxin B was 
confirmed.33 Application of the scientific knowledge acquired in the total synthesis above 
led them to synthesize less demanding (lacking the C4a hydroxyl) analogues of 
viridicatumtoxin B, namely: (±)-V2, (±)-V3, (±)-V4, (±)-V5, and (±)-V6.33  
As a whole, their commendable achievement has set the tone for overall advances in the 
area of design, synthesis, and biological evaluation of analogues of viridicatumtoxin A as 
potential leads for drug discovery.
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Figure 4. Structures of Viridicatumtoxin A and Known Naturally Occurring 
Analogues. 
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Table 1. Abbreviations of Viridicatumtoxins. 
VCT A Viridicatumtoxin A 
VCT B Viridicatumtoxin B 
VCT C Viridicatumtoxin C 
VCT D Viridicatumtoxin D 
VCT E Viridicatumtoxin E 
VCT F Viridicatumtoxin F 
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CHAPTER II 
GENERAL PROCEDURE 
 
 
2.1 Fungal Culture 
 The seed culture of MSX54809 was grown in a Petri dish with a malt extract agar, 
made up of 10 g malt extract, 10 g glucose, and 20 g agar per 1 L of H2O. When adequate 
growth was observed, an inoculum of the fungus from the seed culture was transferred 
into Erlenmeyer flasks containing the media of interest. The flask cultures are left in 
static conditions and allowed to grow for three to four weeks at room temperature. 
Afterwards, the fungus was killed by spraying the culture with MeOH and extracted 
immediately or stored at -18 ˚C until the time of extraction. 
2.2 Solvent Extraction 
 In the Oberlies lab, we work with organic compounds, which are generally more 
soluble in organic solvents like chloroform than in water, an aqueous solvent. Shaking a 
fungal culture in a solution of chloroform and water gives a two-layer partition i.e. the 
organic (non-aqueous) and aqueous layers. Organic compounds will, therefore, be in the 
non-aqueous (organic) layer and vice versa. Finally, this non-aqueous layer is removed 
and is ready for purification to obtain the compound of interest.  
 Extractions for this study, unless otherwise stated, follow the Oberlies laboratory 
extraction protocol, which begins by adding 60 mL 1:1 CHCl3-MeOH mixture to each 
fungal culture and shaking overnight at 100 rpm. The next day each flask is filtered via 
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Buchner funnel. 90 mL CHCl3 and 150 mL H2O were added to the organic filtrate to 
obtain a 4:1:5 CHCl3-MeOH-H2O mixture. This extraction mixture is stirred for half-hour 
with a magnetic stirrer and partitioned in a separatory funnel, and the organic fraction 
was dried down in vacuo. The dried organic fraction is then reconstituted in 100 mL 
CH3CN-MeOH to 100 ml hexanes producing a 3:3:4 CH3CN-MeOH-hexane mixture and 
a second partition is carried out to remove fatty materials from the sample. The defatted 
crude extract, which contains the compound of interest, is then dried in vacuo. 
2.3 Flash Chromatography 
 The first step in the Oberlies laboratory isolation protocol of defatted fungal 
extracts is initial fractionation. Flash chromatography is used for the initial fractionation 
of the mixture of compounds in crude exacts.   
 The initial fractionation in this study is carried out with a flash chromatography 
instrument, Teledyne ISCO CombiFlash Rf, set-up in normal phase with a silica gel 
stationary phase column using hexane, chloroform, and methanol solvent mixture as 
mobile phase. Empty sample cartridges available in various sizes are packed with solid 
samples by means of Celite (a sorbent) and then mounted unto the column. A UV-Vis 
detector and an external evaporative light scattering detector (ELSD) are connected to the 
ISCO system.  The flash chromatography uses a medium pressure pump and yields 
fractions based on polarity. 
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2.4 High Performance Liquid Chromatography (HPLC) 
 Our pure fractions were obtained using a Varian Prostar HPLC system comprising 
of a photodiode array (PDA) detector, a reciprocating two-head pump, a fraction 
collector, an evaporative light scattering detector (ELSD) connected to a computer to read 
the generated data. The HPLC technique for this project involves an Atlantis T3 column 
packed with C-18 sorbent molecules (stationary phase) and a CH3CN-H2O with 0.1% 
formic acid solvent mixture as mobile phase. In contrast to column chromatography, the 
mobile phase is powered through the column by high pressure delivered by the pump. 
After dissolving the sample in a solvent of about 300 µL, the homogenous solution is 
injected into the flow path of the mobile phase. The analyte is separated into distinct 
peaks on a generated chromatogram using optimum elution method as it passes through 
the HPLC column and each peak represents a pure compound. The pure compounds are 
collected as fractions in test tubes arranged in the fraction collector. HPLC columns also 
include, Gemini (C-18), Synergi (C-12), and PFP (C-18) columns to mention a few. 
These columns are used for analytical, semi preparative, or preparative application to 
obtain pure compounds. 
2.5 Ultra Performance Liquid Chromatography (UPLC) 
 UPLC analytical separation technique operates on similar principles to HPLC but 
with increased speed, sensitivity & resolution. UPLC columns are packed with fine 
particles of < 2.0µm thereby resulting in lower flow rate and higher peak capacity, 
reduced run times and minimal solvent consumption. UPLC columns includes, BEH C-
18, BEH C-8, HSS C-18, and HSS T3 among others. An Acquity UPLC system equipped 
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with a BEH C-18 (1.7 mm; 50 × 2.1 mm) column and a flow rate of 0.2 -0.4 mL/min was 
used to confirm the purity of viridicatumtoxin A. The Acquity UPLC system has a binary 
solvent manager that uses two individual pumps to deliver two solvents in parallel 
gradient, sample manager that draws samples from 96-well 1 mL plates and injects into 
the flow stream of the mobile phase, the column heater controlled by the sample manager 
for temperature of 5°C - 65°C, detectors consisting of an ultraviolet (UV) detector called 
PDA that operates between 190 and 500 nm λ, and an ELSD to detect the relative 
abundance of analytes.  
2.6 Mass Spectrometry 
 The Q Exactive Plus mass spectrometer coupled to Water’s Acquity UPLC 
system at the Triad Mass Spectrometry laboratory of UNCG department of chemistry and 
biochemistry was mainly used for precise mass analysis during the course of this study. 
The mass spectrometry (MS) analytical technique is used to determine the amount of an 
analyte in a sample by measuring the mass-to-charge ratio. MS has evolved as a key 
analytical tool in almost all levels of drug discovery due to its high sensitivity and speed 
in the identification of analytes in complex mixtures.  
 The MS is made up of three main components: an ionization source, a mass 
analyzer, and a detector. The UPLC was used as the delivery mechanism for sample 
introduction. The electrospray ionization (ESI) method was employed in the study where 
charged droplets are produced at the tip of the ESI capillary, desolvation of the droplets 
by nebulizing gas and, the production of gas phase ions from the highly charged small 
droplets. Mass analyzers vary in the fundamental way in which they separate species on a 
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mass-to-charge basis. The quadrupole (single or triple) separates ions according to their 
mass-to-charge ratio as they pass through the central axis of electric fields of four parallel 
equidistant rods. The signals from the mass analyzer are received and displayed by the 
detector as a readable spectrum on the computer. 
2.7 Nuclear Magnetic Resonance 
 Nuclear Magnetic Resonance (NMR) spectroscopy generate distinct signals that 
when interpreted provide structural information on the number and position the atoms in 
of an organic compound. These distinct signals are generated from the magnetic nuclear 
spin of atoms when they experience dissimilar milieu in an applied magnetic field. The 
frequency of each signal on the NMR spectrum, relative to tetramethylsilane (TMS), the 
reference standard, is called chemical shifts. NMR spectroscopy is very useful in 
structure elucidation of organic compounds especially for drug discovery purposes. 
 For 1H NMR, the absence or presence of electronegative atom around a proton 
increases or decreases respectively the electron density around the proton. A deshielded 
proton has decreased electron density in an applied magnetic field, thereby shifting its 
signal downfield (left) of the spectrum, while a shielded proton by virtue of its intact 
electron density is seen upfield (right) of the spectrum. The intensities of the signal 
produced is a ratio of the number of equivalent protons generating it. Protons that 
experience comparable magnetic environment are called chemically equivalent protons 
and therefore, are seen as the same signal (singlet) in the NMR spectrum. 
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 NMR signals spectrum usually have peaks that appear as groups of peaks due to 
interaction (coupling) with neighboring proton(s) are usually labeled as singlet doublets 
(2 peaks), triplets (3 peaks), quartets (4 peaks)… multiplet (complex peaks). The distance 
within each group of peaks are called coupling constants, denoted by J.  
 13C NMR is used for carbon NMR because 12C, the most abundant natural carbon 
isotope has a net spin of zero in NMR. The number and position of discrete signals are 
the most important pieces of information conveyed by 13C NMR as there is no correlation 
between each NMR signal and the number of atoms producing it.  
 
Figure 5. Process Flow Chart 
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CHAPTER III 
EXPERIMENTAL 
 
 
3.1 Bioactivity Directed Fractionation 
 Extracts of the filamentous fungus MSX71909 exhibited cytotoxicity (Table 2) 
with the following IC50 values; 1.2 µM against MDA-MB-435 (human melanoma cancer 
cell lines), 10.8 µM against MDA-MB-231 (human breast cancer cell lines) and 11.1 µM 
against OVCAR3 (human ovarian cancer cell lines).  Next, we isolated viridicatumtoxin 
A by bioactivity directed fractionation. Through dereplication protocol by matching full-
scan high-resolution mass spectra and MS/MS spectra from both the positive- and 
negative-ionization modes coupled with UV-absorption maxima and retention times with 
in-house database of over 450 compounds constructed based on cytotoxic fungal 
secondary metabolites, we identified the bioactive compound as viridicatumtoxin A. 
 Three viridicatumtoxin A producing fungal strains from Mycosynthetix were 
utilized in the present study and were identified via ITS sequencing and molecular 
phylogenetic methods.20 Our lab has been systematically investigating the vast 
Mycosynthetix library for anti-cancer drug leads for years.34 These three strains, 
MSX71909, MSX72658, and MSX54809 were identical and can be described as 
Purpureocillium lavendulum.35 
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 Due to the cytotoxic activities exhibited by viridicatumtoxin A, we set up an 
experiment to scale up its production. In addition, we wanted more materials for the 
organic synthesis of the bioactive but scarce analogue, viridicatumtoxin B which we 
would attempt in collaboration with the Croatt lab.    
                                                                                    
Table 2. Cytotoxicity (IC50 Values) Data for Viridicatumtoxin A. 
Compound MDA-MB-435 
(melanoma) 
MDA-MB-231 
(breast) 
OVCAR3 
(ovarian) 
VCT A 1.2 µM 10.8 µM 11.1 µM 
  
 
 The solid-state rice media has been the adopted media for drug-lead screening  
projects based on previous studies.36 The Oberlies-Mycosynthetix drug-lead discovery 
collaboration involves growing fungal samples in solid-state rice media for routine 
chemical and biological analysis.34 
 Therefore, the three in-house fungal strains of Purpureocillium lavendulum, 
namely: MSX72658, MSX71909, and MSX54809, which are known to produce 
viridicatumtoxin A were fermented on solid-state rice media within the same period 
and conditions. The cultures were incubated for four weeks at room temperature. They 
were all extracted at the same time after fermentation using our conventional extraction 
protocol described earlier. After extraction, the five replicates of the extracts were        
 
 
24 
 
to flash chromatography on our Teledyne ISCO CombiFlash Rf, set-up in normal phase 
using hexane, chloroform, and methanol. The fraction containing our compound of 
interest was then purified using preparative High-Performance Liquid chromatography.  
 
Table 3. Reported IC50 Values (µM) for Viridicatumtoxin A and Related 
Analogues.27 
 
Compound 
SW620 
(colon) 
NCI-H460 
(lung) 
KB3-1 
(cervix) 
VCT A 1.0 1.0 2.5 
VCT B 0.6 0.6 1.6 
VCT C 17.4 9.2 11.0 
VCT D 20.7 24.2 >30 
VCT E >30 >30 >30 
VCT F >30 >30 >30 
Spirohexaline 16.7 11.3 6.3 
Previridicatumtoxin 6.0 5.3 4.1 
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Figure 6. Viridicatumtoxin A Production on Rice Media. A comparison of the amount 
of pure viridicatumtoxin A isolated from the three fungal strains. Data plotted are the 
averages ± SE for five replicate cultures per fungal strain. 
 
 
 After statistical analysis of the pure HPLC fractions (Figure 6), MSX54809 was 
determined to be the best viridicatumtoxin A producer.  The research, therefore, 
progressed from this point forward with MSX54809. 
3.2 Optimizing Production of Viridicatumtoxin A via Media Study 
 The next stage in the project was to optimize the production of viridicatumtoxin A 
from MSX54809 via media study. Solid-state rice media has hitherto been established as 
a functional growth medium in which most fungi thrive and produce active compounds, 
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but we hypothesized that it may not be the most functional media for some fungi to 
produce a secondary metabolite of interest.36 
 To determine the most functional growth media to optimize the production of 
viridiactumtoxin A by MSX54809, the fungus was grown in eight media, including the 
established rice media, which are divided into two groups. These two groups are the solid 
and the liquid media groups. Their names and composition are as follows: Rice mix 
(Botan and Basmati variety), Botan Rice ( Botan variety), Cheerios (Multigrain variety), 
Oats (regular breakfast Oats), PDB (Potato Dextrose Broth composed of potato infusion 
and dextrose with an organic acid), MEB (Malt Extract Broth composed of malt extract 
and peptone with an organic acid), SDB (Sabouraud Dextrose Broth composed of 
peptone and dextrose with an organic acid for low pH), YESD (Yeast Extract Soy 
Peptone made up of 1% yeast extract, 2% soy peptone, and 2% dextrose). Peptone serves 
as utilizable source of nitrogen, vitamins, minerals, amino acids, and growth factors while 
dextrose serves as the carbon source. The organic acid favors fungal growth and inhibits 
bacteria growth. 
 The growth of MSX54809 started in a Petri dish by using a malt extract agar, 
made up of 10 g malt extract, 10 g glucose, and 20 g agar per 1 L of H2O. When it is 
considered that the fungus has attained adequate size of growth, then an inoculum of the 
fungus, MSX54809, was transferred into a separate 250 mL Erlenmeyer flask containing 
one of the above listed media. 
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  The cultures were fermented in static conditions for four weeks, after which they 
were killed by spraying with MeOH. The cultures were either extracted immediately 
following step-by-step the protocol stated above or stored at -18 °C until the time of 
extraction (Figure 7). 
 
Figure 7. Fungal Growth on Various Media. Comparison of the amount of fungal 
extracts produced by MSX54809 on eight different media in a flask each.  
 
 
 To determine the concentration (amount) of viridicatumtoxin A in each media, a 
quantitation experiment was designed. Concentrations of ten standard solutions was set 
up to adequately cover the expected concentration range in the extract solutions which 
are the test samples. Starting with 1024 µg/mL and by sequential dilutions: 512 µg/mL, 
256 µg/mL, 128 µg/mL, 64 µg/mL, 32 µg/mL, 16 µg/mL, 8 µg/mL, 4 µg/mL and 2 
µg/mL evenly spread out standard solutions were prepared.
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 The test solutions were prepared to a concentration of 1000 µg/mL each. Both the 
standard solutions and the test samples were prepared in MeOH and 100 µL of each 
solution was pipetted into a 1 mL 96 well plate. A blank with zero concentration of 
analyte was put into the plate to run directly before and directly after the standard 
solutions as controls. 
 For the quantitation studies, a UPLC Acquity system equipped with a BEH C-18 
(1.7 mm; 50 × 2.1 mm) column, using a flow rate of 0.3 mL/min, column and sample 
manager temperatures set at 40 0C and 10 0C respectively. Starting with a gradient of 
45:55% CH3CN – H2O (acidified with 0.1 % formic acid) rising to 100% CH3CN 
between 0 – 8 min and holding 100% CH3CN for 2 mins; 8.0 – 10 min, returning to 
starting conditions and holding it for 10 secs. 
 
Figure 8. Calibration Curve 1 for Viridicatumtoxin A. Area Under Curve (AUC) at 
254 nm vs eight standard concentration levels in MeOH which ran in triplicate. 
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 This study was done in experimental triplicates, and the standard samples were 
run from lowest to highest concentration. The data obtained was graphed as UV 
absorption (254 nm) against concentration. In accordance with Beer’s law, a good linear 
relationship between detector response (UV absorption) and concentration (of standard 
and test solutions) quantified as R2 came up. Hence, the linear fit (y= mx + b) was 
determined for the calibration curve (Figure 8), with y as UV absorption, x as 
concentration, y axis intercept b as zero (i.e. the concentration was zero when the 
absorption was zero), and m as the slope (i.e. the molar absorptivity times the path length 
of 1 cm). Thus, the concentration of viridicatumtoxin A in each media was calculated. 
The cheerios media was determined to have the highest concentration with a 2.5-fold 
increase over the established solid-rice media (Figure 9). 
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Figure 9. Amount of Viridicatumtoxin A in Extract. Comparison of the amount of 
pure viridicatumtoxin A isolated from extracts of MSX54809 on eight different media in 
a flask each.  
 
 
 Flash chromatography was used to fractionate each of the extracts. The extracts 
for fractionation were first prepared by dissolving the samples in CHCl3/MeOH mixture 
and then, pipetting onto evenly spread-out diatomaceous earth known as Celite (a 
sorbent) in a mini bowl. The Celite and the extract samples are mixed thoroughly in the 
mini bowls and left to sit in the laboratory hood for some time to allow the CHCl3/MeOH 
mixture to evaporate, leaving the extract solidly adsorbed onto the Celite. The dried 
extract-Celite complex was broken up with a mortar and pestle and then packed into the 
preselected cartridges. The packed cartridge and a RediSep Rf Si-gel Gold column were 
fitted into position according to manufacturer’s directives.  
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 The initial fractionation of the extracts was carried out using our UV and ELSD 
connected Teledyne ISCO CombiFlash Rf flash chromatography instrument. The 
instrument switches between hexane, chloroform and methanol as mobile phase with a 
flow rate of 18 mL/min. The method gradient of hexane-CHCl3-MeOH started with 
100% hexane which rapidly mixes with CHCl3 until the gradient reaches 100% CHCl3. 
The 100% CHCl3 gradient is sustained for a while before it is mixed in a stepwise 
approach with MeOH until 100% MeOH gradient is attained. This 100% MeOH gradient 
is held till the end of the run. 
 The flash chromatography (Figure 10) for each sample yielded four fractions 
based on polarity. The fractions were then dried in vacuo and transferred by means of 
solvents (CHCl3 and MeOH) into scintillating vials to dry under nitrogen gas lines. After 
drying the fractions, they were analyzed using HRMS to determine which fraction 
contains the mass (based on m/z of 564.1866, [M - H]-) of our compound of interest. This 
was further confirmed with prep-HPLC and 1H-NMR. 
 Preparative and semi preparative HPLC were utilized to purify the compound of 
interest. Sample preparation involves first analyzing the ISCO fractions to optimize the 
preparative conditions. After optimal preparative conditions have been obtained, the 
samples were dissolved in ~300 mL of tetrahydrofuran (THF) and loaded into a 500 µL 
Hamilton syringe.  
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 Reverse-phase preparative HPLC with 40 – 100% CH3CN to H2O (with 0.1% 
formic acid) gradient over 30 mins using Atlantis T3 (C-18) column was utilized for the 
purification of the desired compound which, is viridicatumtoxin A. The initial gradient of 
40% CH3CN – 60% H2O climbed to 100% CH3CN over 30 mins. The 100% CH3CN was 
held for 2 mins before returning to starting conditions in 30 secs in readiness for the next 
run. After each run, the pure sub-fractions (Figure 11) obtained were also dried in vacuo 
and transferred by means of solvents into scintillating vials to dry under nitrogen.  
 The pure fractions were further analyzed by a UPLC/PDA/MS method whereby 
the retention time, UV spectrum, HRMS, and MS/MS were compared with an authentic 
standard. The HRESIMS data (Figure 12) was collected in a Thermo Fisher Scientific Q 
Exactive Plus instrument. This HRMS analysis produced a molecular formula of 
C30H30NO10 [M - H]- based on m/z of 564.1866. Additionally, the 
1H-NMR (Figure 13) 
of the pure compound was acquired in the JEOL ECA-500 NMR spectrometer to 
determine the authenticity of the compound. The amount of the pure viridicatumtoxin A 
tallied with the amount calculated in the extract from the calibration curve (Figure 14). 
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Figure 10. Flash Chromatography of Extracts of MSX54809 (Purpureocillium 
lavendulum). Above is chromatogram of extracts from Cheerios and below is for extracts 
from Rice-Mix. 
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Figure 11. Preparative HPLC of Flash Chromatography Fractions. Above is 
chromatogram of flash chromatography fractions of Purpureocillium lavendulum from 
Cheerios (Top) and below is for Rice-Mix.  
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Figure 12. MS Analysis Data of Viridicatumtoxin A. Top is viridicatumtoxin A 
isolated from the Cheerios Media, Middle is from the Rice-Mix Media and Bottom is the 
Pure Standard. 
Cheerios 
Rice-Mix 
Standard 
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Figure 13. 1H-NMR Data of Viridicatumtoxin A from Cheerios Media.
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Table 4. Pure Viridicatumtoxin A Isolated from Purpureocillium lavendulum in 
Cheerios and Rice-Mix Media. 
Media Notebook Code Amount (mg) 
Cheerios MSX54809-01062-22-2 29.9 
Cheerios MSX54809-01062-22-3 3.7 
 
Total 33.7 
1:1 Rice-Mix MSX54809-01062-23-2 8.6 
1:1 Rice-Mix MSX54809-01062-23-3 0.5 
1:1 Rice-Mix MSX54809-01062-29-2 0.7 
1:1 Rice-Mix MSX54809-01062-29-3 5.7 
1:1 Rice-Mix MSX54809-01062-29-4 1.2 
 
Total 16.6 
 
Figure 14. Amount of Pure VCT A Agrees with Quantitation Studies. 
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 After the quantitation, 77 250 mL Erlenmeyer flasks, 1 2800 mL Erlenmeyer flask 
and 1 large bag of the fungus MSX54809 were cultured and extracted in five batches 
throughout this project. 
 The first batch (Table 5) involved 10 250 mL Erlenmeyer flasks. These were 
cultured following the same protocol described above. After the cultures have grown for 
four weeks, they were combined and extracted using a different protocol.  This started by 
adding 150 mL of acetone to the sample, which was then chopped with spatula and 
allowed to sit for 30 mins at room temperature. The samples were filtered in a vacuum 
via Buchner funnel, and evaporated to an aqueous solution. Twice to the aqueous 
solution, 100 mL of CHCl3 was added. The biphasic solution was stirred for about half-
hour with a magnetic stirrer and partitioned in a separatory funnel, and the organic 
fraction dried down in vacuo. The dried organic fraction is then reconstituted in 100 mL 
of hexane and 100 mL of 1:1 MeOH – CH3CN. A second partition was carried out to 
remove fatty materials from the sample. The defatted crude extract is then dried in vacuo 
and transferred by means of CHCl3 and MeOH into scintillating vials to dry under 
nitrogen gas lines.  
 The second batch of cultures (Table 5) comprised of 24 250 mL Erlenmeyer 
flasks, 1 2800 mL Erlenmeyer flask and 1 large bag of the fungus MSX54809. The 250 
mL flasks were combined and extracted. The 2800 mL Erlenmeyer flask and the large 
bag (each ~8 250 mL Erlenmeyer flasks) were extracted separately. These extractions 
were according to our conventional extraction protocol described earlier.  
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 The third batch (Table 5), which also followed our conventional extraction 
protocol, involved 7 250 mL Erlenmeyer flasks. This was the first attempt to probe the 
growth of MSX54809 on other varieties of cheerios. Two flasks of each variety of berry, 
frosted, honey nut, and multigrain cheerios were used as culture media to ferment 
MSX54809, but the fungus failed to grow in a flask of the berry cheerios media. 
 Batch four (Table 5) was a repeat of batch three experiment but in this case, 4 250 
mL Erlenmeyer flasks of each variety of berry, frosted, honey nut, and multigrain 
cheerios were cultured to ferment MSX54809 and were extracted after four weeks of 
growth. The results showed no significant difference in the growth of the fungus and 
amount of viridicatumtoxin produced across the varieties of cheerios tested. 
 
Table 5. Production of Viridicatumtoxin A across Batches. Amount of extracts and 
isolated viridicatumtoxin A diminished drastically up to batch 4 despite using other 
varieties of cheerios (varied cheerios). 
Batches Media Extract per Flask 
(mg) 
VCT A per Flask 
(mg) 
0 Multigrain Cheerios 211 35 
1 Multigrain Cheerios 69 7.1 
2 Multigrain Cheerios 70 1.5 
3 Varied Cheerios 79 4.2 
4 Varied Cheerios 58 1.2 
5 Multigrain Cheerios 117 15 
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3.3. Production of Viridicatumtoxin A Attenuated 
 By the time prep HPLC of the fourth batch was completed, the production of 
viridicatumtoxin A had waned by about 92% of expected yield.  This occurrence is 
similar to what has been reported in subcultures of endophytic fungal strains, where 
metabolite production becomes attenuated after a series of subculturing exercises.37  
 Following the recommendation of our resident mycologist, we decided to carry 
out quantitation studies to determine which of our 7 in-house slants of MSX54809 still 
retained the best growth potentials.  
 As described above ten calibration standards: 64 µg/mL, 32 µg/mL, 16 µg/mL, 8 
µg/mL, 4 µg/mL, 2 µg/mL, 1 µg/mL, 0.5 µg/mL, 0.25 µg/mL to 0.125 µg/mL were 
prepared. The test samples (from the seven plates of MSX54809) were prepared to a 
concentration of 1000 µg/mL each. Both the calibration standards and the test samples 
were prepared in DMSO, and 200 µL of each solution was pipetted into a 1 mL 96 well 
plate. A blank with zero concentration of analyte was put into the plate to run directly 
before and directly after the standard calibrations as control. For this quantitation study, a 
UPLC Acquity system equipped with a BEH C-18 (1.7 mm; 50 × 2.1 mm), a flow rate of 
0.4 mL/min, column and sample manager temperatures of 40 0C and 10 0C respectively 
was used. The gradient utilized consisted of CH3CN – H2O (with 0.1 % formic acid) 
rising from 45 to 100 % CH3CN between 0 –5 min and holding 100% CH3CN for 2 mins; 
5.0 –7.0 min, returning to starting conditions and holding it for 10 secs. 
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 The study was done in biological and experimental triplicates. The data obtained 
was graphed (Figure 15) as instrument’s response (Area under the Curve) and 
concentration of standard solutions. Thus, a good linear relationship quantified as R2 
emerged. Quantitation of the analyte, viridicatumtoxin A, was based on comparing the 
instrument’s response acquired from the analyte in each test sample with instrument’s 
response from a set of calibration standards of known concentration. Thus, the 
concentration of viridicatumtoxin A in each test sample was calculated (Figure 16).  
 
Figure 15. Calibration Curve 2 for Viridicatumtoxin A. Area Under Curve (AUC) 
measured by UPLC-ESIMS vs eight standard concentration levels in DMSO which ran in 
triplicate. 
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Figure 16. Quantitation of VCT A in Agar Extract. A, B and C are replicates of the 
same fungal colony. 
  
 
 The appearance of the plate cultures of the Purpureocillium lavendulum, 
MSX54809, after four weeks of growth clearly showed variations in color and 
morphology across and within replicate plates (Figure 17). The results showed that plate 
six replicates were the most consistent replicates used for this study. It was also observed 
across replicate plates that guttate formation, which was present in plate six replicates, 
corresponded to increased viridicatumtoxin A production.38 Therefore, we concluded to 
proceed with the next round of culturing with an inoculum of Purpureocillium 
lavendulum from plate six. 
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Figure 17. Plates Showing Growth of Purpureocillium lavendulum on Agar Media. 
Variations of morphology within and across plates can be seen. 
 
 
 
 The last batch (Table 5) was made up of 8 250 mL Erlenmeyer flasks in which the 
fungus was grown for four weeks and the cultures were combined and extracted in line 
with our conventional extraction protocol. The results showed a rise in the yield of 
viridicatumtoxin A from an average of ~ 2 mg per flask in the last round of extraction to 
~ 15 mg representing an 86% increase.
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Figure 18. Summary of Viridicatumtoxin A Production per Flask. 
 
 
 The amount of viridicatumtoxin A quantitated in extract via calibration curve and 
the amount obtained from preparative HPLC tallied well when figures 6 and 11 above are 
compared. Hence, the attenuation of viridicatumtoxin A production suffered by 
Purpureocillium lavendulum, MSX54809, in the course of this studies is attributable to 
domestication.37 
   Fungal metabolites, like viridicatumtoxin A, are produced to enhance the 
competitiveness of a fungus in its complex and hostile habitats. When this aggressiveness 
is quenched by taking the fungus away from its natural habitat to the serene atmosphere 
of the laboratory, the fungus’ competitive nature is suppressed. Hence, the ability of the 
fungi to produce secondary metabolites, is therefore hampered.
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CHAPTER IV 
CONCLUSION 
 
 
4.1. Biosynthesis of Viridicatumtoxin A 
 The isolation of a secondary metabolite with a tetracyclic framework from fungi 
other than the bacterial group called Streptomyces elicited investigations into the 
biosynthesis of viridicatumtoxin A.39  Isotopic incorporation of 13C, 14C and 18O from 
different sources into viridicatumtoxin A by supplying the isotopes into a culture of 
Penicillium exparzsum was the first experiment aimed at understanding the biosynthesis 
of viridicatumtoxin A.40 
 In 2010, by means of DNA pyrosequencing, guided gene deletions and RNA 
silencing of the genome of a viridicatumtoxin A producing fungus, Penicillium 
aethiopicum, the gene clusters involved in the biosynthesis were located.30 These gene 
clusters, named as “vrt”, are fascinating examples of a hybridized polyketide-isoprenoid 
biosynthetic pathway in fungi.30  
 A pathway based on results from the acetate labelling and the gene cluster studies 
was put forward for the biosynthesis of viridicatumtoxin A. It is initiated by an 
asparagine-derived malonamoyl-CoA starter unit culminating in the formation of 
viridicatumtoxin A at step 14.30
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 The finding that viridicatumtoxin A is the last product of the proposed 
biosynthetic pathway also supported our earlier consideration of attenuation due to 
domestication. This prompted us to affirm  that the decline in the production of 
viridicatumtoxin A in the course of this study from Purpureocillium lavendulum, 
MSX54809, may have been caused by diminution in secondary metabolism due to 
domestication or sub-culturing (as described above).37  
4.2. Mechanism of Antibacterial Activities 
 Viridicatumtoxin A, along with viridicatumtoxin B possess antibacterial activities 
by reason of their tetracyclic naphthacenedione core. The mechanism of action for their 
antibacterial properties was reported by Tomoda et al. to be through the inhibition of 
undecaprenyl pyrophosphate (UPP) synthase. UPP synthase is an enzyme essential to the 
biosynthesis of peptidoglycan in bacteria.  
 The assay involved calculating the amount of phosphate liberated from inorganic 
pyrophosphatase (IPP) obtained from Saccharomyces cerevisiae when incubated with 
UPP synthase and viridicatumtoxin A at 37˚C. Viridicatumtoxin A inhibited UPP 
synthase activity with an IC50 value of 4.0 µM. This result further differentiated 
viridicatumtoxin A from the tetracycline family, which inhibits protein synthesis in 
bacteria by binding to the 30s subunit of ribosome.
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4.3 Mechanism of Anticancer Activities 
 Viridicatumtoxin A and B have demonstrated anticancer properties in cytotoxicity 
assays. The IC50 values obtained from these tests have raised the prospects of 
viridicatumtoxin A becoming a cancer therapeutic agent in the foreseeable future. The 
realization of this lofty goal depends among others on determining the actual mechanism 
by which viridicatumtoxin A inhibits cancer cell lines.  
4.4 Semi-synthesis Challenge  
 The oxidation of the hydroxyl group on C-5 of viridicatumtoxin A to a ketone, 
thereby forming viridicatumtoxin B, which is the second part of this project remains a 
work in progress. The main challenge of this experiment is the ability to efficiently and 
selectively oxidize only the hydroxyl group on C-5 of viridicatumtoxin A while avoiding 
over oxidation to carboxylic acid and oxidation of other adjacent hydroxy groups. The 
development of highly chemo-selective synthetic conditions is overcoming this 
challenge.  
4.5. Toxicity    
 Reports of toxicity in rats and mice that were dosed with viridicatumtoxin A have 
raised concerns about the toxicity of this compound to humans.26 These concerns need to 
be resolved through appropriate and adequate in vivo evaluations in experimental animals 
before any application for clinical trials can be considered. 
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4.6 Future Considerations 
 Viridicatumtoxin A and analogues constitute indeed an interesting class of 
compounds that nature has given us. Their antibacterial properties, which currently favors 
the Gram-positive bacteria are well-documented but investigations into their cytotoxic 
activities is beginning to gather momentum. 
 Preliminary results of the semi-synthesis of viridicatumtoxin B, our goal number 
two (in collaboration with the Croatt lab), have shown great progress towards the 
development of a novel synthetic protocol that affords optimum yields of pure 
viridicatumtoxin B. The possibility of making nontoxic synthetic analogues with 
surpassing cytotoxicity is also within the area of consideration.  
  More screening of the vast Mycosynthetix library for additional viridicatumtoxin 
A producing fungi with the aim of further raising the optimization bar which will serve as 
production factory to conduct more successful synthetic experiments. It is suggested that 
these fungal strains when discovered should be tested on cheerios to determine their 
levels of output in terms of viridicatumtoxin A production. 
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